OVID
Ovid Therapeutics Inc.
Key Financials
Revenue
$7.3M
↑ 1181.3%
Operating Income
$-42439000
↑ 31.4%
EPS (Diluted)
$-0.74
↑ 3.9%
Total Liabilities
$20.3M
↓ 15.3%
Net Income
$-17414000
↑ 34.1%
Total Assets
$150.9M
↑ 63.8%
Shareholders' Equity
$130.7M
↑ 91.5%
Cash & Equivalents
$13.2M
↓ 50.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 144 | 8/14/2026 | View on SEC |
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| SCHEDULE 13G/A | 8/13/2026 | View on SEC |
| 10-Q | 8/13/2026 | View on SEC |
| 8-K | 8/13/2026 | View on SEC |
| SCHEDULE 13G | 7/29/2026 | View on SEC |
| 4 | 7/8/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | OVID |
| Company Name | Ovid Therapeutics Inc. |
| CIK | 1636651 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 212-776-4381 |